Shihan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shihan Chen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Fan Li
Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
18 shared publications - Gonghui Li
Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
18 shared publications - Haohua Lu
Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
18 shared publications - Lifeng Ding
Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
18 shared publications - Liqun Xia
Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
18 shared publications - Liyang Li
New South Wales Department of Health, Australia
18 shared publications
Latest Publications
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Calibration and discrimination via the C-for-benefit method for m6A DE prediction.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Calibration and discrimination via the C-for-benefit method for m6A DE prediction.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Related to Fig. 3d. The regulatory capacity of m6A machineries.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Related to Fig. 3d. The regulatory capacity of m6A machineries.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Representative IHC slides and intergroup comparison of immunofluorescence signals and predicted DE values in SRR-cohort.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Representative IHC slides and intergroup comparison of immunofluorescence signals and predicted DE values in SRR-cohort.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Related to Fig. 6d. Enrichment analysis for top important molecular features
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Related to Fig. 6d. Enrichment analysis for top important molecular features
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
PCA of the WER-target expression profile in the TCGA cohort.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
PCA of the WER-target expression profile in the TCGA cohort.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Related to Fig. 4g. Summary of estimated m6A ADE across different cancer types in the TCGA cohort.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Related to Fig. 4g. Summary of estimated m6A ADE across different cancer types in the TCGA cohort.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods Note 1 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Factorization of TCGA clinical data variables as ordinal categorical variables for TCGA
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods Note 1 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Factorization of TCGA clinical data variables as ordinal categorical variables for TCGA
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Survival analysis for W system across cancer types.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Survival analysis for W system across cancer types.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Valid WER-target associations validated in this study.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Valid WER-target associations validated in this study.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Related to Fig. S2a. Summary of PCA analysis.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
Related to Fig. S2a. Summary of PCA analysis.